Skip to main content
NCBI home page
British Journal of Industrial Medicine logoLink to British Journal of Industrial Medicine
. 1988 Dec;45(12):818–823. doi: 10.1136/oem.45.12.818

Serum type III procollagen peptide in asbestos workers: an early indicator of pulmonary fibrosis.

A Cavalleri 1, F Gobba 1, L Bacchella 1, F Luberto 1, A Ziccardi 1
PMCID: PMC1009702  PMID: 3219307

Abstract

Serum type III procollagen peptide (PIIIP) concentrations were determined in 36 male workers exposed to asbestos fibres in the production of asbestos cement items and in 13 healthy male controls. Mean (SD) PIIIP serum concentrations were 9.3 (1.5) ng/ml (range 7-12) in the controls and 13.7 (3.5)ng/ml (range 7.5-20) in the asbestos workers; the difference was statistically significant (p less than 0.01). The exposed workers were subdivided according to presence or absence of radiological signs of asbestosis and intensity and duration of exposure. PIIIP serum values of workers with asbestos related interstitial fibrosis were the highest of the groups at 14.6 (2.3) ng/ml. In workers with heavy exposure the PIIIP values were significantly related to duration of exposure (r = 0.95; p less than 0.01). PIIIP serum values may be a useful index for the early diagnosis of asbestos induced pulmonary fibrosis and its use should be considered as part of the biological monitoring of exposed workers.

Full text

PDF
818

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barnes M. J., Morton L. F., Bennett R. C., Bailey A. J., Sims T. J. Presence of type III collagen in guinea-pig dermal scar. Biochem J. 1976 Jul 1;157(1):263–266. doi: 10.1042/bj1570263. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bateman E. D., Turner-Warwick M., Adelmann-Grill B. C. Immunohistochemical study of collagen types in human foetal lung and fibrotic lung disease. Thorax. 1981 Sep;36(9):645–653. doi: 10.1136/thx.36.9.645. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Becklake M. R., Fournier-Massey G., Rossiter C. E., McDonald J. C. Lung function in chrysotile asbestos mine and mill workers of Quebec. Arch Environ Health. 1972 Jun;24(6):401–409. doi: 10.1080/00039896.1972.10666115. [DOI] [PubMed] [Google Scholar]
  4. Bégin R., Cantin A., Berthiaume Y., Boileau R., Péloquin S., Massé S. Airway function in lifetime-nonsmoking older asbestos workers. Am J Med. 1983 Oct;75(4):631–638. doi: 10.1016/0002-9343(83)90449-7. [DOI] [PubMed] [Google Scholar]
  5. Bégin R., Martel M., Desmarais Y., Drapeau G., Boileau R., Rola-Pleszczynski M., Massé S. Fibronectin and procollagen 3 levels in bronchoalveolar lavage of asbestos-exposed human subjects and sheep. Chest. 1986 Feb;89(2):237–243. doi: 10.1378/chest.89.2.237. [DOI] [PubMed] [Google Scholar]
  6. Chiappino G. Quali effetti nell'uomo da basse esposizioni agli asbesti. Med Lav. 1985 May-Jun;76(3):179–191. [PubMed] [Google Scholar]
  7. Copes R., Thomas D., Becklake M. R. Temporal patterns of exposure and nonmalignant pulmonary abnormality in Quebec chrysotile workers. Arch Environ Health. 1985 Mar-Apr;40(2):80–87. doi: 10.1080/00039896.1985.10545894. [DOI] [PubMed] [Google Scholar]
  8. Cotes J. E., Rossiter C. E., Higgins I. T., Gilson J. C. Average normal values for the forced expiratory volume in white Caucasian males. Br Med J. 1966 Apr 23;1(5494):1016–1019. doi: 10.1136/bmj.1.5494.1016. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Enterline P. E. Epidemiologic basis for the asbestos standard. Environ Health Perspect. 1983 Oct;52:93–97. doi: 10.1289/ehp.835293. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Fessler J. H., Fessler L. I. Biosynthesis of procollagen. Annu Rev Biochem. 1978;47:129–162. doi: 10.1146/annurev.bi.47.070178.001021. [DOI] [PubMed] [Google Scholar]
  11. Forni A., Guerreri M. C., Chiappino G. Nuovi metodi di indagine nelle pneumopatie professionali: il lavaggio broncoalveolare. Esperienza dell'Istituto di Medicina del Lavoro della Università di Milano. Med Lav. 1985 Jan-Feb;76(1):11–16. [PubMed] [Google Scholar]
  12. Gadek J. E., Fells G. A., Zimmerman R. L., Crystal R. G. Role of connective tissue proteases in the pathogenesis of chronic inflammatory lung disease. Environ Health Perspect. 1984 Apr;55:297–306. doi: 10.1289/ehp.8455297. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Kirk J. M., Bateman E. D., Haslam P. L., Laurent G. J., Turner-Warwick M. Serum type III procollagen peptide concentration in cryptogenic fibrosing alveolitis and its clinical relevance. Thorax. 1984 Oct;39(10):726–732. doi: 10.1136/thx.39.10.726. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Kirk J. M., Heard B. E., Kerr I., Turner-Warwick M., Laurent G. J. Quantitation of types I and III collagen in biopsy lung samples from patients with cryptogenic fibrosing alveolitis. Coll Relat Res. 1984 May;4(3):169–182. doi: 10.1016/s0174-173x(84)80039-4. [DOI] [PubMed] [Google Scholar]
  15. Last J. A., Reiser K. M. Collagen biosynthesis. Environ Health Perspect. 1984 Apr;55:169–177. doi: 10.1289/ehp.8455169. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Laurent G. J., McAnulty R. J., Corrin B., Cockerill P. Biochemical and histological changes in pulmonary fibrosis induced in rabbits with intratracheal bleomycin. Eur J Clin Invest. 1981 Dec;11(6):441–448. doi: 10.1111/j.1365-2362.1981.tb02011.x. [DOI] [PubMed] [Google Scholar]
  17. Low R. B., Cutroneo K. R., Davis G. S., Giancola M. S. Lavage type III procollagen N-terminal peptides in human pulmonary fibrosis and sarcoidosis. Lab Invest. 1983 Jun;48(6):755–759. [PubMed] [Google Scholar]
  18. Madri J. A., Furthmayr H. Collagen polymorphism in the lung. An immunochemical study of pulmonary fibrosis. Hum Pathol. 1980 Jul;11(4):353–366. doi: 10.1016/s0046-8177(80)80031-1. [DOI] [PubMed] [Google Scholar]
  19. Murphy R. L., Jr, Ferris B. G., Jr, Burgess W. A., Worcester J., Gaensler E. A. Effects of low concentrations of asbestos. Clinical, environmental, radiologic and epidemiologic observations in shipyard pipe coverers and controls. N Engl J Med. 1971 Dec 2;285(23):1271–1278. doi: 10.1056/NEJM197112022852301. [DOI] [PubMed] [Google Scholar]
  20. Murphy R. L., Jr, Gaensler E. A., Ferris B. G., Fitzgerald M., Solliday N., Morrisey W. Diagnosis of "asbestosis". Observations from a longitudinal survey of shipyard pipe coverers. Am J Med. 1978 Sep;65(3):488–498. doi: 10.1016/0002-9343(78)90775-1. [DOI] [PubMed] [Google Scholar]
  21. Nerlich A. G., Nerlich M. L., Langer I., Demling R. H. Release of amino-terminal procollagen peptides in paraquat-induced acute pulmonary fibrosis. Exp Mol Pathol. 1984 Jun;40(3):311–319. doi: 10.1016/0014-4800(84)90048-0. [DOI] [PubMed] [Google Scholar]
  22. Okazaki I., Maruyama K., Kobayashi Y., Lilis R., Suzuki Y. Serum type III procollagen peptide: indicator for pulmonary fibrosis: II. Application in 80 asbestos insulation workers. Am J Ind Med. 1987;11(4):439–446. doi: 10.1002/ajim.4700110406. [DOI] [PubMed] [Google Scholar]
  23. Okazaki I., Maruyama K., Okuno F., Suzuki H., Aoyagi K., Sera Y. [Serum type III procollagen peptide in patients with pneumoconiosis]. J UOEH. 1983 Dec 1;5(4):461–467. doi: 10.7888/juoeh.5.461. [DOI] [PubMed] [Google Scholar]
  24. Okazaki I., Miura K., Kobayashi Y., Maruyama K., Yoshimatsu H., Tanaka T. Serum type III procollagen peptide: indicator for pulmonary fibrosis. I. A tool for early detection of pulmonary fibrosis as a complication in cancer therapy. Keio J Med. 1986 Jun;35(2):107–115. doi: 10.2302/kjm.35.107. [DOI] [PubMed] [Google Scholar]
  25. Okuno F., Maruyama K., Okazaki I., Arai M., Suzuki H. [Serum type III procollagen peptide in diagnosis of lung fibrosis due to silicosis and bleomycin toxicity]. J UOEH. 1985 Sep 1;7(3):291–297. doi: 10.7888/juoeh.7.291. [DOI] [PubMed] [Google Scholar]
  26. Rohde H., Vargas L., Hahn E., Kalbfleisch H., Bruguera M., Timpl R. Radioimmunoassay for type III procollagen peptide and its application to human liver disease. Eur J Clin Invest. 1979 Dec;9(6):451–459. doi: 10.1111/j.1365-2362.1979.tb00912.x. [DOI] [PubMed] [Google Scholar]
  27. Rom W. N. Commentary: research on the mechanisms of the occupational lung diseases. Arch Environ Health. 1984 May-Jun;39(3):186–189. doi: 10.1080/00039896.1984.9939522. [DOI] [PubMed] [Google Scholar]
  28. Seyer J. M., Hutcheson E. T., Kang A. H. Collagen polymorphism in idiopathic chronic pulmonary fibrosis. J Clin Invest. 1976 Jun;57(6):1498–1507. doi: 10.1172/JCI108420. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Trivedi P., Cheeseman P., Portmann B., Hegarty J., Mowat A. P. Variation in serum type III procollagen peptide with age in healthy subjects and its comparative value in the assessment of disease activity in children and adults with chronic active hepatitis. Eur J Clin Invest. 1985 Apr;15(2):69–74. doi: 10.1111/j.1365-2362.1985.tb00147.x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Industrial Medicine are provided here courtesy of BMJ Publishing Group

RESOURCES